|Systematic (IUPAC) name|
|Molar mass||552.5345 g/mol|
Saredutant (SR-48,968) is a drug which acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May of 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder..
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|35px||This drug article relating to the nervous system is a stub. You can help ssf by expanding it.|
- http://www.sanofi-aventis.com/binaries/Lettre18_FR_Web_acc_tcm29-25341.pdf Letter to the stockholders of Sanofi-Aventis on May 2009